Physician profile
Donald Baseman
NPI 1326120635
$3,736.21
in general payments reported to CMS, 2019-2025
28 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $670 · 2021: $650 · 2022: $525 · 2023: $639 · 2024: $422 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $690.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $406.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $338.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $296.30 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $226.06 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.07 | 2019-2024 | |
| Amgen INC. | $178.53 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $175.77 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $158.68 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $147.56 | 2020-2024 | Livalo |
| Merck Sharp & Dohme LLC | $137.12 | 2019-2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $110.03 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $106.66 | 2023-2025 | Synthroid |
| Novo Nordisk INC | $96.03 | 2019-2025 | Wegovy |
| Esperion Therapeutics, INC. | $89.74 | 2020-2024 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $79.63 | 2020 | |
| Sanofi-Aventis U.S. LLC | $48.89 | 2019 | |
| Medtronic, INC. | $38.98 | 2023 | Stealthstation S8 Platform |
| Takeda Pharmaceuticals U.S.A., INC. | $34.68 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $29.55 | 2023 | Onpattro |
| Inspire Medical Systems, INC. | $29.46 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $19.74 | 2019 | |
| Eisai INC. | $19.25 | 2021 | |
| Almatica Pharma LLC | $16.12 | 2022 | |
| Radius Health, INC. | $14.83 | 2020 | |
| Ibsa Pharma INC. | $13.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Astellas Pharma US INC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Baseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.